Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis

Newsome, Philip N.; Allison, Michael; Andrews, P A; Auzinger, G.; Day, Christopher P.; Ferguson, James; Henriksen, Peter; Hübscher, Stefan G.; Manley, Harold J.; McKiernan, Patrick; Millson, Charles; Mirza, D.; Neuberger, James; Oben, Jude A.; Pollard, S.; Simpson, Ken; Thorburn, Doug; Tomlinson, Jeremy W.; Wyatt, John

doi:10.1136/gutjnl-2011-300886

Cited by 73 publications

(71 citation statements)

References 188 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…цироз внаслідок нАСГ сьогодні є третім за частотою показанням для тран-сплантації печінки в США і включає 12% пацієнтів із списку очікування на трансплантацію у Велико-британії. Виживання пацієнта і трансплантата при пересадці печінки при нАСГ порівнянне з іншими показаннями [16,39]. Хоча рецидив нАСГ після тран-сплантації досить імовірний, виникаючи у 4-25% па-цієнтів, це не впливає на виживаність трансплантата.…”

Section: лекціїunclassified

“…приблизно в 7% пацієнтів з компенсованим цирозом печінки внаслідок нАжХп/нАСГ протягом 10 років розвивається Гцк, причому близько 50% з них або вимагають трансплантації печінки, або вми-рають внаслідок печінкових ускладнень [10]. Ризик розвитку Гцк при цирозі внаслідок нАжХп/нАСГ можна порівняти з таким при алкогольному цирозі або цирозі внаслідок гепатиту С. на сьогодні близь-ко 12% всіх трансплантацій печінки в США викону-ються з приводу цирозу внаслідок нАжХп/нАСГ [39]. Середня тривалість життя хворих з нАжХп менше, ніж у популяції.…”

unclassified

See 1 more Smart Citation

Non-alcoholic fatty liver disease: incidence, natural history, new approaches to diagnostic and treatment

Tkach¹,

Чеверда²

2016

CE&ES

View full text Add to dashboard Cite

show abstract

Section: лекціїunclassified

unclassified

Non-alcoholic fatty liver disease: incidence, natural history, new approaches to diagnostic and treatment

Tkach¹,

Чеверда²

2016

CE&ES

View full text Add to dashboard Cite

show abstract

“…The increase in the number of patients with advanced liver disease secondary to NASH, as well as associated hepatocelullar carcinoma, will impact on the potential future demand for Liver Transplantation (LT) [11].…”

Section: Introductionmentioning

confidence: 99%

A Review of Pharmacological Treatments of NASH

Siqueira

Sanyal

2015

GHOA

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) encompasses the entire spectrum of fatty liver disease in individuals without significant alcohol consumption and affects up to a third of the population in many developed countries. Approximately 10-30% of patients with NAFLD will progress to non-alcoholic steatohepatitis (NASH), which is associated with hepatocellular injury and inflammation resulting in progressive liver fibrosis, liver failure and liver cancer. The increase in the number of patients with advanced liver disease secondary to NASH, as well as associated hepatocellular carcinoma, will impact on the potential future demand for Liver Transplantation (LT) and also increase the cardiovascular mortality. Despite these large numbers of pharmacological agents that have been used to treat NASH, none of them have yet been shown to improve clinically meaningful outcomes. Also the long term safety of several agents remain to be established.

show abstract

“…296,297 With CVEs as a leading cause of death after transplantation, intervention strategies that target modifiable risk factors for CVE (eg, obesity, diabetes, hypertension, dyslipidemia, smoking, and renal dysfunction (such as reduced renal function or albuminuria) will be key for improving long-term outcomes in kidney and liver transplant recipients. [298][299][300] This section describes CVD and metabolic disorders in kidney and liver transplant recipients, and the risk factors for CVEs in these transplant populations. This is followed by the management of cardiovascular risk after kidney and liver transplantation.…”

Section: Cardiovascular Complications After Kidney and Liver Transplamentioning

confidence: 99%

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

et al. 2017

View full text Add to dashboard Cite

Short-term patient and graft outcomes continue to improve after kidney and liver transplantation, with 1-year survival rates over 80%; however, improving longer-term outcomes remains a challenge. Improving the function of grafts and health of recipients would not only enhance quality and length of life, but would also reduce the need for retransplantation, and thus increase the number of organs available for transplant. The clinical transplant community needs to identify and manage those patient modifiable factors, to decrease the risk of graft failure, and improve longer-term outcomes. COMMIT was formed in 2015 and is composed of 20 leading kidney and liver transplant specialists from 9 countries across Europe. The group's remit is to provide expert guidance for the long-term management of kidney and liver transplant patients, with the aim of improving outcomes by minimizing modifiable risks associated with poor graft and patient survival posttransplant. The objective of this supplement is to provide specific, practical recommendations, through the discussion of current evidence and best practice, for the management of modifiable risks in those kidney and liver transplant patients who have survived the first postoperative year. In addition, the provision of a checklist increases the clinical utility and accessibility of these recommendations, by offering a systematic and efficient way to implement screening and monitoring of modifiable risks in the clinical setting. 12 Department of Gastroenterology and Hepatology, Erasmus MC, University Hospital Rotterdam, the Netherlands. 13 Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Belgium.14 Abdominal Transplant Surgery, Microbiology and Immunology Department, University Hospitals KU Leuven, Belgium. 15 Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, IMIBIC, CIBERehd, Spain. www.transplantjournal.com S1 S olid organ transplantation has evolved from an experimental procedure to an established treatment option for many types of end-stage organ failure. Both patient and graft outcomes are continuing to improve, and 1-year patient and graft survival currently exceed 80%.1,2 However, survival rates gradually decline over the long term. In kidney transplant, 5-and 10-year graft survival rates in Europe are 77% and 56%, and for liver transplant, 64% and 54% (Figures 1 and 2). 3,4 Although most European countries have seen an increase in both living and deceased donation, transplantation is not available to all who would benefit from the procedure, and there is considerable morbidity and mortality for those listed for transplant.6 Therefore, maximizing long-term graft survival and reducing the need for retransplantation is paramount, not only in improving outcomes for the recipients but also for those awaiting a graft. The improvement in outcomes is predominantly due to reduction in (Transplantation. 2017;101:S1-S41). The authors were approached by Astellas to discuss the practical implementation o...

show abstract

Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis

Cited by 73 publications

References 188 publications

Non-alcoholic fatty liver disease: incidence, natural history, new approaches to diagnostic and treatment

Non-alcoholic fatty liver disease: incidence, natural history, new approaches to diagnostic and treatment

A Review of Pharmacological Treatments of NASH

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

Contact Info

Product

Resources

About